Rezolute Inc
NASDAQ:RZLT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (19.1), the stock would be worth $-16.86 (621% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.7 | $3.24 |
0%
|
| Industry Average | 19.1 | $-16.86 |
-621%
|
| Country Average | 22.9 | $-20.16 |
-723%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
$344.9m
|
/ |
Jan 2026
$-84.2m
|
= |
|
|
$344.9m
|
/ |
Jun 2026
$-74.2m
|
= |
|
|
$344.9m
|
/ |
Jun 2027
$-71.5m
|
= |
|
|
$344.9m
|
/ |
Jun 2028
$-30.3m
|
= |
|
|
$344.9m
|
/ |
Jun 2029
$-133.5m
|
= |
|
|
$344.9m
|
/ |
Jun 2030
$157.2m
|
= |
|
|
$344.9m
|
/ |
Jun 2031
$234.3m
|
= |
|
|
$344.9m
|
/ |
Jun 2032
$341.6m
|
= |
|
|
$344.9m
|
/ |
Jun 2033
$375.8m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Rezolute Inc
NASDAQ:RZLT
|
298.1m USD | -3.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 89.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 29.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
Rezolute Inc
Glance View
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 26 full-time employees. The company went IPO on 2011-12-23. The firm's lead clinical asset, RZ358, is an antibody therapy in Phase II b development as a potential treatment for Congenital Hyperinsulinism (CHI), an ultra-rare pediatric genetic disorder. Its second clinical asset, RZ402, is a selective and potent Plasma Kallikrein Inhibitor (PKI) being developed as a potential oral therapy for the chronic treatment of Diabetic Macular Edema (DME), is in Phase I development. The clinical study conducting by the Company is called RIZE - An open-label multiple-dose study of RZ358 in Patients with Congenital Hyperinsulinism.
